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Abstract
Although the randomised controlled trial is the “gold standard” for
studying the efficacy and safety of medical treatments, it is not
necessarily free from bias. When patients do not follow the protocol for
their assigned treatment, the resultant “treatment contamination” can
produce misleading findings. The methods used historically to deal with
this problem, the “as treated” and “per protocol” analysis techniques,
are flawed and inaccurate. Intention to treat analysis is the solution most
often used to analyse randomised controlled trials, but this approach
ignores this issue of treatment contamination. Intention to treat analysis
estimates the effect of recommending a treatment to study participants,
not the effect of the treatment on those study participants who actually
received it. In this article, we describe a simple yet rarely used analytical
technique, the “contamination adjusted intention to treat analysis,” which
complements the intention to treat approach by producing a better
estimate of the benefits and harms of receiving a treatment. This method
uses the statistical technique of instrumental variable analysis to address
contamination. We discuss the strengths and limitations of the current
methods of addressing treatment contamination and the contamination
adjusted intention to treat technique, provide examples of effective uses,
and discuss how using estimates generated by contamination adjusted
intention to treat analysis can improve clinical decision making and
patient care.
Introduction
The recent European Randomized Study of Screening for
Prostate Cancer
1 concluded that 1400 patients would need
prostatespecificantigenscreeninginordertopreventonedeath
fromprostatecancer.Thisnumberwillbeusedinmeta-analyses,
cost effectiveness analyses, and clinical guidelines. But is it
accurate?Inthestudy,nearly20%ofpeopleassignedtoreceive
prostate specific antigen screening didn’t undergo a single test
in 10 years. In a similar American randomised controlled trial,
2
40% of participants who weren’t supposed to receive prostate
specificantigenscreeningwereactuallytested.Boththesetrials
wereanalysedandinterpretedasthoughallparticipantsfollowed
the treatment they were randomised to. If participants had in
factadheredtotheirassignedinterventionasrandomised,would
the results have been different? Are the results accurate when
it comes to advising individual patients whether they should be
screened?
Randomised controlled trials are the “gold standard” for
examining the efficacy and safety of medical interventions
becausetheyareconsideredfreefrombias.However,whatwas
seen in the recent prostate specific antigen trials is common in
randomised controlled trials and makes the published data less
reliable. When study participants do not receive the treatment
to which they were randomised, the flaw called “treatment
contamination” is created. Treatment contamination can occur
through treatment non-adherence (not receiving the
recommended intervention because of treatment intolerance or
patient preference) and treatment crossover (receiving the
intervention intended for the other group in a trial). Just as
non-adherence is common in clinical practice, treatment
contamination in randomised controlled trials is not a small or
infrequent problem—some of our largest trials have
contamination of more than 30%.
3-6
In this paper, we describe a method called the “contamination
adjusted intention to treat” (CA ITT) analysis that better
estimatesthebenefitsofreceivingatreatment.CAITTanalysis
uses an established statistical technique called instrumental
variables (IVs) analysis to adjust for the bias created by
contamination. CA ITT analyses could be an excellent
complementtotraditionalanalysesbutarerarelyusedinclinical
trials, which have traditionally emphasised analytical
simplicity.
7-10Weoutlinetheproblemoftreatmentcontamination
and how it is currently addressed, describe IVs and CA ITT,
how they can be used in clinical trials, and summarise the
benefits and limitations of the CA ITT technique.
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• As treated: Method of analysis for randomised controlled trials in which all patients are analysed on the basis of the treatment ultimately
received, regardless of the treatment to which they were randomly assigned.
• Contamination adjusted intention to treat: Method of analysis for randomised controlled trials in which all patients are analysed
as they were randomised and then the result adjusted for treatment contamination by using an instrumental variable.
• Crossover: When a study participant receives the intervention for the group to which he or she has not been assigned.
• Instrumental variable: An analytical technique, traditionally used in non-randomised research studies, that uses a variable associated
with the factor under study but not directly associated with the outcome variable or any potential confounders.
• Intention to treat: Method of analysis for randomised controlled trials in which all patients are analysed as they were randomised,
regardless of behaviour or treatment received.
• Loss to follow-up: When a participant in a study is not involved in the outcome assessment. This issue is not addressed in this paper.
• Non-adherence: When a study participant does not receive the assigned therapy, whatever the cause and no matter how legitimate
the reason. Non-adherence is often used differently in clinical practice from in experimental research.
• Per protocol: Method of analysis for randomised controlled trials in which individuals are included in the analysis only if they followed
the assigned protocol and are removed from the analysis entirely if they do not follow protocol.
• Treatment contamination: Any time the study participant does not follow the protocol for the assigned treatment. In a study with no
treatment contamination, the results of the intention to treat and contamination adjusted intention to treat analyses will be identical.
Background: What do we do now, and
what’s wrong with it?
How to address treatment contamination in randomised
controlledtrialshasbeendebatedforyears.Themostcommonly
used approaches historically are the “as treated” and “per
protocol” techniques, which have appropriately fallen out of
favour(table⇓).Inastreatedanalyses,participantsareanalysed
entirely on the basis of treatment received (that is, according to
their behaviour, not their random assignment). In per protocol
analyses,participantswhofailtofollowtheprotocolaresimply
droppedfromthestudy(thatis,includedorexcludedaccording
totheirbehaviour).Althoughtheseapproachesseemreasonable,
people’s behaviours are strongly non-random, with
non-adherents generally being less healthy and less health
conscious than those who adhere to treatment.
11 12 Analysing
trial data by behaviour removes the benefit of randomisation,
yielding results that are generally biased.
11-13
Guidelines now recommend that randomised controlled trials
use intention to treat analysis.
14 15 In intention to treat analysis,
sometimes called “analyse as randomised” analysis,
14 15
participants are analysed on the basis of the treatment arm to
which they were initially assigned, regardless of their ultimate
treatment exposure. Intention to treat analysis avoids the flaws
oftheastreatedandperprotocolapproachesandshouldalways
betheinitialanalysisofarandomisedcontrolledtrial.However,
intention to treat analysis ignores treatment contamination
altogether. What often goes unappreciated is the fact that
intention to treat analysis answers the question: “how much do
study participants benefit from being assigned to a treatment
group?” This can be important information to policy makers
and health planners, but patients and clinicians generally want
to know the answer to a different question: “what are the risks
and benefits of receiving a treatment?”
Using instrumental variables to help us
understand results of randomised
controlled trials
Whenphysicianswereinvestigatingwhethermaternalsmoking
leads to poor birth outcomes, they determined that evidence
from traditional longitudinal studies was unreliable because
smokersandnon-smokersarebehaviourallydifferentinsomany
waysasidefromsmokingstatus.Asolutiontothisproblemwas
found through tobacco taxes. Throughout the 1970s and 1980s,
Americanstateshadmanyandvariedincreasesintobaccotaxes
that clearly altered smoking rates across states. Increases in
cigarettetaxesseemunlikelytoaffectbirthoutcomesotherthan
through the effect on smoking. Researchers used a statistical
technique known as IV analysis to estimate the impact of
smoking on birth outcomes by comparing birth outcomes and
changesinsmokingrateswithstatechangesincigarettetaxes.
16
IV techniques were designed to learn from natural experiments
(thatis,changesinpeople’senvironmentsorexposuresunrelated
totheirindividualchoicesorbehaviours),inwhichanunbiased
“instrument” (such as change in tobacco taxation level) makes
theexposureofinterest(suchasanindividual’ssmokinghabits)
more or less likely but has no other effect, either directly or
indirectly, on the outcome. IV analysis assesses how the
instrument predicts the exposure and the outcome, then uses
that information to understand how the exposure predicts the
outcome. This type of two stage analysis is used often in the
socialsciencesandisbecomingcommoninobservationalstudies
in medicine.
17-20 Medical examples of IVs in observational
studies include comparing the outcomes among patients whose
doctors prefer first generation (conventional) versus second
generation (atypical) antipsychotics,
19 analysing the effects of
dramatic changes in copayment on medication adherence and
subsequent health outcomes among patients with chronic heart
failure,
21 and using distance from a catheterisation lab to
approximate the benefit of intensive therapy for heart attacks.
17
Even the random assortment of genetic information has been
used as an IV called “Mendelian randomisation”—a genetic
variant acts as an instrumental variable to help disentangle the
confounded causal relation between phenotype and disease.
22
Despite their theoretical appeal, valid IVs are uncommon. The
most common IV in medicine is randomisation within a
randomised controlled trial that has treatment contamination.
IVanalysiscanbridgethegapbetweenthemorepolicyfocused
question posed by intention to treat analyses and the patient
focused question of biological efficacy.
8 23 24
The concept behind a CA ITT analysis is quite simple. The
randomised controlled trial is treated as an IV, with treatment
assignment as the “instrument.” The effect of treatment
assignment on outcome observed (intention to treat analysis) is
adjusted by the percentage of assigned participants who
ultimately receive the treatment (contamination adjustment).
This way the effect of treatment receipt on the risk of the
outcome can be obtained (fig⇓). If a patient stops taking a
medication early, the measured non-adherence can be adjusted
for with CA ITT and the biases of as treated and per protocol
analyses can be avoided. The intention to treat and the CA ITT
estimatesprovidecomplementaryinformation,andbothresults
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7 8 24-28IVestimatorsareavailable
in most major statistical packages.
Loss to follow-up, where a patient does not participate in
planned follow-up evaluations in a trial or cannot be evaluated
at all, is also a major cause of bias in randomised controlled
trials, but is a separate and statistically more difficult problem
(for a discussion of this topic, see Dunn et al
10).
Real world examples
CA ITT analysis has been used for randomised controlled trials
in the past, but rarely, and has gone by several different names,
including“complieraveragecausaleffects,”
9 23IVs,
29 30efficacy
estimator,
31 and preference based analysis.
26 For example, one
study found that vitamin A supplementation in malnourished
children reduced mortality by 41% when a traditional intention
to treat analysis was used.
31 Once the high mortality rate of the
treatmentnon-adherentswasaccountedfor,however,receiving
supplementswasfoundtoreducemortalitybytwothirds(72%).
A recent CA ITT analysis determined that faecal occult blood
testing reduces mortality from colorectal cancer by 25% if the
patient returns the sample cards, rather than by 19%, the value
associated with being randomised to receive the test kit.
32
Adjusting randomised trials for treatment contamination could
allow more nuanced understanding of the medical literature.
Forexample,the1994ScandinavianSimvastatinSurvivalStudy
(4S)
33 found a 20% greater effect of simvastatin on cardiac
events than did the 2002 Heart Protection Study (HPS).
34
Although other explanations are possible, differences in
treatment contamination clearly played a role. The Heart
Protection Study, which unlike the Scandinavian Simvastatin
Survival Study occurred after statins were in general use, had
much higher treatment contamination. This difference alone
would account for almost all of the difference between the
intention to treat estimates reported in these two trials.
What are the benefits and limitations of
CA ITT estimates?
The primary benefit of CA ITT analysis is improved accuracy
in estimating the size of treatment benefit for a patient who
receives the treatment. Why is this important? The exact effect
size of a treatment is relevant whenever you weigh a treatment
againstnegativeconsequenceslikesideeffects,againsttreatment
costsincosteffectivenessanalyses,oragainstanothertreatment.
For example, if many patients stop taking a weight loss drug
because of side effects, an intention to treat analysis would
measure early treatment side effects appropriately but assess
longtermweightlossandsideeffectsquitepoorly.Patientsand
clinicians would be better informed by having information on
both estimates: the proportion of people who stop the medicine
because of side effects; and the degree of weight loss and side
effects in patients who continue taking the medication. The
comparative effectiveness of two chemotherapeutic regimens
withdifferentcontaminationratescouldsimilarlybemisleading
to patients and clinicians.
8 32
In addition, the estimate of benefit in many cost effectiveness
analysesisbasedontheoutcomeofanintentiontotreatanalysis,
buttheestimatedtreatmentcostassumes100%adherence.This
disparity will result in underestimation of the treatment’s cost
effectiveness and will particularly disadvantage effective but
costly treatments.
CA ITT analysis of randomised controlled trials has some
limitations. Treatment contamination is not always assessed in
clinical trials and can be quite difficult to measure, especially
in trials of medications for chronic conditions. Partial
contamination and adherence can complicate analysis
substantially.Mostimportantly,theCAITTtechniqueassumes
that if non-adherents had received the treatment, the treatment
would have had the same medical effect as it did in adherents.
Ifnon-adherentorcrossoverpatientsexhibitadifferenttreatment
benefit from adherents, a CA ITT analysis will be biased. This
issue increases the need to accurately assess heterogeneity of
treatment effect among adherents.
35 However, although the
assumptions of CA ITT can potentially be violated, the
assumptionsaremorereasonablethanthoseofstandardintention
totreatanalysis—thatpatientswhocrossovertoactivetreatment
get no benefit and those who fail to receive an assigned
intervention benefit as though they did receive it.
Advanced IV analysis
There are more detailed IV adjustment techniques than the CA
ITTtechniquedescribedherethatcanaccountforcomplicating
factors such as partial contamination (for example, partial
medication adherence or early dropout),
29 36 time dependent
contamination (such as in surgery trials where control group
participants have surgery late in the study),
29 participants lost
to follow-up,
37 and non-adherence in randomised equivalency
studies (that is, comparing two active treatment arms).
26 These
techniques,althoughsometimessignificantlymorecomplicated
than CA ITT, have a strong theoretical basis and can
substantially improve the reliability of results.
Conclusion
Randomised controlled trials in which no control participants
crossovertoactivetreatmentandallthoserandomisedtoactive
treatment tolerate and adhere to their assigned treatment do not
need to be analysed using CA ITT. However, trials do not often
proceed like this and are unlikely to do so more often in the
future, so an intention to treat analysis will rarely provide an
accurate estimate of treatment benefits for those receiving a
treatment.
In major trials, efforts should be taken to limit and quantify
treatment contamination with close follow-up of study
participants, surveys to assess and optimise adherence, and use
of intermediate measures of adherence and effectiveness (such
as following change in low density lipoprotein in cholesterol
trials that are powered for survival). However, contamination
is not always just a nuisance factor—it can demonstrate
important factors such as how well patients tolerate treatment
side effects.
Once deviations from random assignments occur, regardless of
the reason, scientists running trials should examine how
treatment contamination has affected their results. Although
traditional intention to treat analysis (that is, the effect of
recommending the treatment to study participants) should still
be used for the primary analysis of a randomised controlled
trial, the CA ITT approach is also important because it better
estimates the efficacy of the treatment in patients who actually
receive it.
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When patients in a clinical trial do not follow the protocol for their assigned treatment, the resultant “treatment contamination” can produce
misleading findings
The older methods used to deal with this problem, the “as treated” and “per protocol” analysis techniques, are flawed and inaccurate
Intention to treat analysis estimates the effect of recommending a treatment to study participants, not the effect of receiving the treatment
A technique that we call “contamination adjusted intention to treat analysis” can complement the intention to treat approach by producing
a better estimate of the benefits and harms of receiving a treatment
The contamination adjusted intention to treat analysis uses the statistical technique of instrumental variable analysis to address
contamination
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Table 1| Different methods of analysing a randomised controlled trial
Negatives Benefits Explanation
Results in non-random omission bias Easy to calculate
Tries to address patient oriented question
Analyses by treatment received As treated
Results in non-random omission bias Easy to calculate
Tries to address patient oriented question
Omits all participants who do not follow
protocol
Per protocol
Underestimates value of receiving the
treatment
Easy to assess
Provides good estimate of the effect of
recommending a treatment to study population
Analyses by randomisation, ignores
whether treatment received
Intention to treat
Overestimates population level treatment
benefits
Somewhat more difficult calculation
Provides good estimate of an individual’s risks and
benefits of receiving a treatment
Analyses by randomisation, adjusts for
whether treatment received
Contamination adjusted
intention to treat
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Fig 1 Analysis of randomised controlled trials. In per protocol and as treated analyses (A), random assignment is ignored,
creating less reliable results. In intention to treat analyses (B), only the effect of randomisation is assessed, not the effect
of receiving the intervention. The two stage contamination adjusted intention to treat approach (C) uses assignment and
intervention received to calculate the effect of receiving the treatment
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